Ana Sahores
Buenos Aires, C, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.
Journal: British journal of cancer
Published: October 03, 2025
Flurbiprofen inhibits cAMP transport by MRP4/ABCC4 increasing the potency of gemcitabine treatment in PDAC cell models.
Journal: International journal of biological macromolecules
Published: July 22, 2024
The xenobiotic transporter ABCC4/MRP4 promotes epithelial mesenchymal transition in pancreatic cancer.
Journal: Frontiers in pharmacology
Published: May 14, 2024
The mRNA vaccine for the treatment of pancreatic cancer is here to stay
Journal: Medicina
Published: August 15, 2023
Ceefourin-1, a MRP4/ABCC4 inhibitor, induces apoptosis in AML cells enhanced by histamine.
Journal: Biochimica et biophysica acta. General subjects
Published: November 04, 2022
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
Journal: International journal of cancer
Published: September 03, 2021
Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity.
Journal: Cancer research
Published: April 29, 2020
Multidrug transporter MRP4/ABCC4 as a key determinant of pancreatic cancer aggressiveness.
Journal: Scientific reports
Published: April 21, 2020
Identification of MRP4/ABCC4 as a Target for Reducing the Proliferation of Pancreatic Ductal Adenocarcinoma Cells by Modulating the cAMP Efflux.
Journal: Molecular pharmacology
Published: December 05, 2018
Involvement of histamine H1 and H2 receptor inverse agonists in receptor's crossregulation.
Journal: European journal of pharmacology
Published: September 25, 2018
Last Updated: 09/26/2026